Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

ATOS Atossa Therapeutics Inc

1,05

0,02 (1,94%)

Zuletzt aktualisiert: 18:39:30

Verzögert um 15 Minuten

Form ARS - Annual Report to Security Holders

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Atossa Therapeutics Charts.

News Atossa Therapeutics Inc

Atossa Set to Join Russell 3000® Index Effective June 28, 2024
Montag 17 Juni 2024 (1 Woche vor) • GlobeNewswire Inc.

Atossa to Present at the Sidoti Small-Cap Investor Conference
Mittwoch 5 Juni 2024 (3 Wochen vor) • GlobeNewswire Inc.

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
Dienstag 28 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Freitag 24 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Donnerstag 23 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
Mittwoch 15 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Form DEL AM - Delaying amendment
Dienstag 14 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Montag 13 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Montag 13 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 13 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Montag 13 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Form PRE 14A - Other preliminary proxy statements
Freitag 10 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Atossa Therapeutics Inc News-Artikel

BNP Paribas Issuance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen